DE60022069T3 - Nicht-anaphylaktische formen des grasspollenallergens ph1 p 6 und deren verwendung - Google Patents
Nicht-anaphylaktische formen des grasspollenallergens ph1 p 6 und deren verwendung Download PDFInfo
- Publication number
- DE60022069T3 DE60022069T3 DE60022069T DE60022069T DE60022069T3 DE 60022069 T3 DE60022069 T3 DE 60022069T3 DE 60022069 T DE60022069 T DE 60022069T DE 60022069 T DE60022069 T DE 60022069T DE 60022069 T3 DE60022069 T3 DE 60022069T3
- Authority
- DE
- Germany
- Prior art keywords
- phl
- rphl
- ige
- molecule
- allergen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000013566 allergen Substances 0.000 claims abstract description 64
- 238000012217 deletion Methods 0.000 claims abstract description 25
- 230000037430 deletion Effects 0.000 claims abstract description 25
- 230000002163 immunogen Effects 0.000 claims abstract description 18
- 230000000774 hypoallergenic effect Effects 0.000 claims abstract description 12
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 11
- 238000003745 diagnosis Methods 0.000 claims abstract description 6
- 229940046528 grass pollen Drugs 0.000 claims description 47
- 241000746983 Phleum pratense Species 0.000 claims description 38
- 239000013574 grass pollen allergen Substances 0.000 claims description 22
- 206010020751 Hypersensitivity Diseases 0.000 claims description 18
- 208000026935 allergic disease Diseases 0.000 claims description 17
- 230000007815 allergy Effects 0.000 claims description 16
- 238000009169 immunotherapy Methods 0.000 claims description 9
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 5
- 206010048908 Seasonal allergy Diseases 0.000 claims description 5
- 201000004338 pollen allergy Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 101710127735 Pollen allergen Phl p 6 Proteins 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000001694 hyposensitizing effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 38
- 208000010668 atopic eczema Diseases 0.000 description 38
- 230000000172 allergic effect Effects 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 33
- 241000283973 Oryctolagus cuniculus Species 0.000 description 31
- 229960004784 allergens Drugs 0.000 description 28
- 239000002245 particle Substances 0.000 description 22
- 239000012634 fragment Substances 0.000 description 20
- 229960001340 histamine Drugs 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000009257 reactivity Effects 0.000 description 11
- 230000002052 anaphylactic effect Effects 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 239000000020 Nitrocellulose Substances 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 229920001220 nitrocellulos Polymers 0.000 description 8
- 102000011195 Profilin Human genes 0.000 description 7
- 108050001408 Profilin Proteins 0.000 description 7
- 206010040914 Skin reaction Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000035483 skin reaction Effects 0.000 description 7
- 231100000430 skin reaction Toxicity 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 235000007238 Secale cereale Nutrition 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000002983 circular dichroism Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 244000025254 Cannabis sativa Species 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000003651 basophil Anatomy 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229940030577 timothy grass pollen extract Drugs 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 4
- 240000004296 Lolium perenne Species 0.000 description 4
- 241000209049 Poa pratensis Species 0.000 description 4
- 241000209056 Secale Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001142 circular dichroism spectrum Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 3
- 244000075850 Avena orientalis Species 0.000 description 3
- 235000007319 Avena orientalis Nutrition 0.000 description 3
- 235000018185 Betula X alpestris Nutrition 0.000 description 3
- 235000018212 Betula X uliginosa Nutrition 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 244000273256 Phragmites communis Species 0.000 description 3
- 235000014676 Phragmites communis Nutrition 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000013575 birch pollen allergen Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013573 pollen allergen Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 210000000712 G cell Anatomy 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000209510 Liliopsida Species 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 244000082988 Secale cereale Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 101100004297 Caenorhabditis elegans bet-1 gene Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 101001086866 Sus scrofa Pulmonary surfactant-associated protein B Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000007198 pollen germination Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9903950 | 1999-10-29 | ||
| SE9903950A SE9903950D0 (sv) | 1999-10-29 | 1999-10-29 | Non-anaphylactic forms of grass pollen allergen and their use |
| PCT/SE2000/002062 WO2001030816A1 (en) | 1999-10-29 | 2000-10-24 | NON-ANAPHYLACTIC FORMS OF GRASS POLLEN Ph1 p 6 ALLERGEN AND THEIR USE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE60022069D1 DE60022069D1 (de) | 2005-09-22 |
| DE60022069T2 DE60022069T2 (de) | 2006-06-08 |
| DE60022069T3 true DE60022069T3 (de) | 2011-05-05 |
Family
ID=20417569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60022069T Expired - Lifetime DE60022069T3 (de) | 1999-10-29 | 2000-10-24 | Nicht-anaphylaktische formen des grasspollenallergens ph1 p 6 und deren verwendung |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1224215B2 (enExample) |
| JP (2) | JP4881526B2 (enExample) |
| AT (1) | ATE302213T1 (enExample) |
| AU (1) | AU778066B2 (enExample) |
| CA (1) | CA2387260C (enExample) |
| DE (1) | DE60022069T3 (enExample) |
| DK (1) | DK1224215T4 (enExample) |
| ES (1) | ES2246904T5 (enExample) |
| SE (1) | SE9903950D0 (enExample) |
| WO (1) | WO2001030816A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT503530A1 (de) | 2006-04-28 | 2007-11-15 | Biomay Ag | Polypeptid mit allergenen eigenschaften |
| EP2042193A1 (en) | 2007-09-28 | 2009-04-01 | Biomay AG | RNA Vaccines |
| CN102811735B (zh) * | 2010-01-14 | 2015-09-09 | 默克专利股份公司 | 由于脯氨酸残基突变而具有降低的致敏性的禾本科的第6组过敏原的变异体 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19713001A1 (de) * | 1997-03-27 | 1998-10-01 | Merck Patent Gmbh | Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung |
-
1999
- 1999-10-29 SE SE9903950A patent/SE9903950D0/xx unknown
-
2000
- 2000-10-24 CA CA2387260A patent/CA2387260C/en not_active Expired - Lifetime
- 2000-10-24 AU AU13193/01A patent/AU778066B2/en not_active Expired
- 2000-10-24 AT AT00975093T patent/ATE302213T1/de active
- 2000-10-24 ES ES00975093T patent/ES2246904T5/es not_active Expired - Lifetime
- 2000-10-24 WO PCT/SE2000/002062 patent/WO2001030816A1/en not_active Ceased
- 2000-10-24 DK DK00975093.6T patent/DK1224215T4/da active
- 2000-10-24 DE DE60022069T patent/DE60022069T3/de not_active Expired - Lifetime
- 2000-10-24 JP JP2001533813A patent/JP4881526B2/ja not_active Expired - Lifetime
- 2000-10-24 EP EP00975093A patent/EP1224215B2/en not_active Expired - Lifetime
-
2011
- 2011-06-14 JP JP2011132059A patent/JP2011236217A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2387260C (en) | 2015-12-08 |
| DK1224215T3 (da) | 2005-12-19 |
| EP1224215B1 (en) | 2005-08-17 |
| DE60022069D1 (de) | 2005-09-22 |
| ATE302213T1 (de) | 2005-09-15 |
| AU778066B2 (en) | 2004-11-11 |
| SE9903950D0 (sv) | 1999-10-29 |
| AU1319301A (en) | 2001-05-08 |
| EP1224215A1 (en) | 2002-07-24 |
| EP1224215B2 (en) | 2010-10-06 |
| JP4881526B2 (ja) | 2012-02-22 |
| JP2003513023A (ja) | 2003-04-08 |
| CA2387260A1 (en) | 2001-05-03 |
| DE60022069T2 (de) | 2006-06-08 |
| JP2011236217A (ja) | 2011-11-24 |
| ES2246904T5 (es) | 2011-03-01 |
| ES2246904T3 (es) | 2006-03-01 |
| DK1224215T4 (da) | 2011-01-24 |
| WO2001030816A1 (en) | 2001-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vrtala et al. | Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from Timothy grass (Phleum pratense) pollen | |
| DE60022069T3 (de) | Nicht-anaphylaktische formen des grasspollenallergens ph1 p 6 und deren verwendung | |
| EP1515988B1 (de) | Dna-sequenz und rekombinante herstellung des graspollen-allergens phl p4 | |
| WO2005058936A2 (de) | Dna-sequenz und rekombinante herstellung des graspollen-allergens lol p 4 | |
| US8440200B2 (en) | Non-anaphylactic forms of grass pollen Ph1 p 6 allergen and their use | |
| AT503296B1 (de) | Protein-allergen-derivat | |
| EP1171604A2 (de) | Dna-sequenz und rekombinante herstellung eines graminaen-allergens | |
| EP1629006B1 (de) | Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität | |
| EP1532169B1 (de) | Varianten des majorallergens phl p 1 aus lieschgras | |
| DE102004035337A1 (de) | Varianten der Gruppe 1-Allergene aus Poaceae mit reduzierter Allergenität und erhaltener T-Zellreaktivität | |
| EP2523684A1 (de) | Varianten der gruppe 6-allergene der süssgräser mit reduzierter allergenität durch mutagenese von prolinresten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: PHADIA AB, UPPSALA, SE Owner name: VALENTA, RUDOLF, THERESIENFELD, AT |
|
| 8366 | Restricted maintained after opposition proceedings | ||
| R082 | Change of representative |
Ref document number: 1224215 Country of ref document: EP Representative=s name: JOCHEN WAECHTER, 80805 MUENCHEN, DE |